Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tic-Tac Trial: HITHOC and pleurectomy for malignant pleural effusion
2026-526109-13-00Phase 3Withdrawn
- Sponsor
- University of Turin
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in malignant pleural effusion (MPE) and pleural neoplasm (4 arms), sponsored by University of Turin. Primary endpoint: Progression-free survival (HITHOC vs control). Planned start Aug 2026; status: withdrawn.
02
Drugs
cisplatin
03
Conditions
malignant pleural effusion (MPE)pleural neoplasm
Beyond the preview
Go deeper on 2026-526109-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526109-13-00.